ARMATURA operates in the field of innovative nutritional support,
bridging the gap between pharmaceutical treatment and conventional dietary supplements.
Its goal is to provide meaningful reinforcement of the body and to improve the
daily life of people facing serious and demanding health challenges,
always with respect for medical practice and for the patient.

A central pillar of ARMATURA’s philosophy is Molecular Activation Technology, an
advanced biotechnological process that enhances the biological activity of natural active ingredients.
Through this technology, high bioavailability and
rapid utilization of the ingredients are achieved, even at lower concentrations,
ensuring optimal effectiveness and increased safety.

This technology is applied across the company’s entire portfolio. A characteristic example
is OCOXIN, a formulation designed for the complementary nutritional support of patients
undergoing oncology treatments. OCOXIN aims to support the body during chemotherapy and
radiotherapy, contributing to improved tolerance
to treatment and to the overall quality of life of patients, through a scientifically validated
and human-centered approach.
Learn more, by visiting our website https://www.msd.gr/ ..

About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company specializing in the discovery, development,
and commercialization of prescription medicines in Oncology, Rare Diseases, and
BioPharmaceuticals, including Cardiovascular, Renal and Metabolic
diseases, Respiratory diseases, and Immunology. Headquartered in Cambridge, United Kingdom.
AstraZeneca operates in more than 100 countries, and its innovative
medicines are used by millions of patients worldwide.
Learn more: https://www.astrazeneca.com/country-sites/greece.html ..

Brains I.C.S. (Brains Innovative Consulting Services) is a modern Greek consulting firm, founded in 2022, with a clear focus on strategic analysis, policy design, digital transformation and the integration of emerging technologies in areas of high social and developmental importance. Operating at the intersection of the public and private sectors, the firm serves as a trusted partner for dialogue, decision support, evidence-based advisory services and implementation, with an emphasis on solutions that are practical, implementable, and deliver measurable outcomes.

Brains I.C.S. is guided by a philosophy that combines scientific knowledge, strategic thinking, and a deep understanding of both institutional and operational environments. The company invests in methodological rigour, transparency, and continuous adaptation to evolving social, economic, and technological challenges, supporting decision-making with long-term impact.

Its core expertise spans Healthcare, Energy, and Technology, leveraging contemporary approaches and tools (including AI and IoT) to support strategic planning, programme maturation, and complex implementation processes. Brains I.C.S. is distinguished by its ability to bridge diverse needs and priorities, delivering solutions characterised by realism, consistency, and added value.

Behind its operations stands a multidisciplinary and highly capable team of consultants and domain experts, bringing complementary skills in strategy, public policy, digital technologies, and sector-specific knowledge. Working closely with clients and partners, the team helps translate strategy into action and enables sustainable outcomes.

The CMT Prooptiki is a consulting and management company specializingin the fields of health and social care. Founded in 1992 and based in Athens, the company has over 30 years of continuous presence and proven experience in the design, implementation, and evaluation of interventions at both national and European levels.

Our mission is to support organizations and institutions through evidence-based analysis, modern management tools, and practical solutions, enabling them to implement meaningful change, enhance efficiency, and improve the quality of their services and processes. We work with a holistic 360° approach, combining an understanding of the social dimensions of care, expertise in service organization, and analysis of real population needs, with the aim of delivering targeted, realistic, and measurable solutions.

Our strength lies in our people. Our multidisciplinary team includes health economists, strategic and operational planning professionals, healthcare practitioners specialized in health policy, IT and data analytics experts, as well as experienced project management and implementation professionals.

Our work is reinforced by a broad and active network of partnerships in Greece and across Europe, including public authorities, private companies, academic institutions, civil society organizations, and international bodies, with whom we have developed long-standing relationships of trust.

Our services include, among others, health strategy and policy design, operational planning and evaluation, development of care models and integrated patient pathways, community-based and patient-centered interventions, as well as projects in health economics, with a strong focus on efficient resource allocation and evidence-based decision support.

Gilead Sciences is a pioneering biotechnology company that researches and develops
innovative therapies in areas where significant unmet medical needs exist.
Our primary goal is to help patients suffering from life-threatening diseases.
We envision a better and healthier world for everyone, and this vision drives our mission.
Thanks to our innovative treatments, millions of
people around the world are living with improved health and quality of life.
Our therapeutic focus areas include HIV
infection and Viral Hepatitis, COVID-19, as well as Oncology.
We remain committed to investing in science
and research, providing therapeutic options to
patients, and addressing major contemporary
public health challenges for the benefit of future generations.
Gilead Sciences was founded in 1987 in Foster City, California, USA, and employs more than
17,000 people worldwide. In Greece, the company has been active since 2001 and offers
original treatments for HIV/AIDS,
Hepatitis B, D and C, Hematologic/Oncologic diseases, COVID-19, Serious Systemic Mycoses,
and Cystic Fibrosis.
Today, Gilead Sciences Greece employs 52 people who focus on medical, regulatory,
and commercial activities.
Learn more, by visiting our website https://www.msd.gr/ ..

In MSD we are joining forces to achieve a common target:
Harnessing the power of leading-edge science to improve the lives of people around the world.
For more than 130 years, we have brought hope to
people by discovering and developing important medicines and vaccines.
We aspire to be a globally leading biopharmaceutical company,
focusing on intensive research to deliver innovative therapeutic solutions that advance the
prevention and treatment of diseases in both humans and animals.
We foster a diverse and inclusive workplace and operate responsibly to help create a safe,
sustainable, and healthy future for all people and communities.
.

MSD in Greece
Since 2010, MSD has been bringing its vision to life in Greece: to improve people’s lives by
offering treatments in the fields of oncology, vaccines, infectious diseases, diabetes, and
cardiology, addressing needs across all stages of life. At the same time, the company ensures
that its activities have a positive impact on
society by implementing initiatives that contribute to a sustainable Greece and by developing
partnerships that invest in the country’s productivity and growth.
Today, MSD employs more than 250 dedicated
employees in Greece, providing an excellent working environment certified as a “Great Place
to Work.”
.
In addition, in 2024, MSD was once again recognized for its commitment to sustainability,
reaffirming its position among the “most sustainable companies”
in Greece.
More information is available in the new Impact Report 2023/2024
which is on our website and on our social media channels: LinkedIn, Facebook,
Twitter and YouTube.
Learn more, by visiting our website https://www.msd.gr/ ..

The Servier is an independent international pharmaceutical company governed by a nonprofit foundation, committed to making a meaningful social impact for patients and contributing to a sustainable world.

Its unique governance model ensures its independence, while supporting long-term innovation, with 100% of its profits reinvested in the Group’s development.

As a world leader in hypertension and venous diseases and a major player in cardiometabolism Servier drives transformative innovation to support patients with chronic conditions and improve their day-to-day lives through a holistic approach, which includes making patient adherence and control a priority across the globe.

The ambition of Servier is to become a leading player in rare cancers, which is why the Group invests heavily in oncology, allocating close to 70% of its R&D budget to this field. Servier develops therapies that are more targeted and more effective. Bolstered by its success in oncology, Servier has expanded into neurology, a key driver of future growth. The Group is focused on a select number of Servier rare neurological diseases, where accurate patient profiling enables targeted therapeutic responses through precision medicine. To open up wider access to high-quality, affordable care, Servier also offers an extensive range of generic medicines, building on well-established brands in France, Eastern Europe, and Brazil. In all its activities, and at every stage of the medicine life cycle, the Group integrates the patient’s voice.

Headquartered in France, Servier operates in around 140 countries. In 2023-2024, the Group, which employs over 22,000 people worldwide.